41 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
to $1 billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease … focused on advancing innovative solutions to influenza, as well as other infectious diseases with future pandemic potential.”
“Just as the COVID-19
8-K
VIR
Vir Biotechnology Inc
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
of new, innovative vaccines and therapeutics for COVID-19. Vir will use such funds to support the development of VIR-7229 through a Phase 1 clinical … into the BARDA Agreement to help advance the Company’s development of a full portfolio of innovative solutions to address influenza and potentially other
8-K
EX-99.1
VIR
Vir Biotechnology Inc
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
-share payments to be received from GSK expected to fund the Company’s innovative portfolio for several years through key inflection points –
SAN … ), awarded Vir a multi-year contract with the potential for an investment of up to $1.0 billion to advance the development of a full portfolio of innovative
8-K
VIR
Vir Biotechnology Inc
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
of innovative solutions to address influenza and potentially other infectious disease threats. The BARDA Agreement provides for potential total investments
8-K
EX-99.1
VIR
Vir Biotechnology Inc
24 Feb 22
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
4:27pm
and as treatment for hospitalized COVID-19 patients; and advance new innovative pan-coronavirus solutions. Importantly, our strong cash position allows us … the advancement of innovative platform technologies in the development of broadly neutralizing antibodies designed to provide a “vaccinal effect” aimed
DEFA14A
pihe fevz
14 May 24
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
9gykuscfs9slxnxzu v8
5 May 22
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results
12:00am
DEF 14A
wq1pxlpwvtfp 7d
6 Apr 20
Definitive proxy
4:52pm
S-1
EX-10.16
2f9ishekuw0i1zgk
3 Sep 19
IPO registration
4:40pm
DRS/A
EX-10.16
gktcwb 17
7 Aug 19
Draft registration statement (amended)
12:00am
424B4
xcthubmpi
11 Oct 19
Prospectus supplement with pricing info
5:31pm
S-1/A
vatq5h57 s9
30 Sep 19
IPO registration (amended)
6:12am
DRS
d3ns9opq ork
27 Jun 19
Draft registration statement
12:00am
DRS/A
l7ojn
7 Aug 19
Draft registration statement (amended)
12:00am
S-1
z48lot ds
3 Sep 19
IPO registration
4:40pm